Insiders · THRX

David Kerstein

Officer at Theseus Pharmaceuticals, Inc. (THRX)

David Kerstein has filed 3 insider reports with the SEC since February 2022, as officer at Theseus Pharmaceuticals, Inc. (THRX). The latest filing, on March 2, 2023, reports grant or award at Theseus Pharmaceuticals, Inc. (THRX).

Filings
3
Companies
1
Bought on market
None
Sold on market
None

Companies where David Kerstein is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Theseus Pharmaceuticals, Inc. logo
THRX
Theseus Pharmaceuticals, Inc.
OfficerMar 2, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare David Kerstein with

Questions about David Kerstein

What is David Kerstein's role at Theseus Pharmaceuticals, Inc.?
David Kerstein reports to the SEC as officer at Theseus Pharmaceuticals, Inc. (THRX), according to the latest filing on March 2, 2023.
Has David Kerstein bought or sold stock recently?
No open-market purchases or sales by David Kerstein are on file. The filings report grant or award.
How do I get alerts when David Kerstein files?
Follow David Kerstein on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by David Kerstein (SEC CIK 0001796388). Totals count each trade once, skipping amendments whose original is on file, from Feb 24, 2022 on. View on SEC EDGAR · Get this as JSON